<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1532">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537572</url>
  </required_header>
  <id_info>
    <org_study_id>R2020-1002</org_study_id>
    <nct_id>NCT04537572</nct_id>
  </id_info>
  <brief_title>A Comparison of Sample Collection Methods for SARS-COV-2 Antibody Testing</brief_title>
  <official_title>A Comparison of Sample Collection Methods for SARS-COV-2 Antibody Testing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salveo Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Salveo Diagnostics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The negative global consequences of the COVID-19 pandemic has prompted efforts to develop
      efficient laboratory testing protocols that can be quickly scaled in a practical way.
      Traditional phlebotomy requirements for antibody testing (venipuncture) often serve as a
      barrier to widespread population testing since they typically require dedicated facilities
      and personnel training. Conversely, antibodies are typically very stable in blood and require
      very little testing volume, which make antibody tests well suited to be run on samples
      collected via finger-stick, saliva, or other self-administered collection devices. Salveo
      Diagnostics is a CLIA/CAP certified clinical laboratory that routinely performs testing for
      anti-SARS-Cov-2 antibodies. The purposes of this protocol are to 1) assess the feasibility of
      streamlined sample collection procedures for assessing COVID-related immune status, and 2) to
      provide a mechanism for securing sequential samples in COVID positive and negative patients
      to support additional studies (e.g. investigating timing of anti-SARS-CoV-2 antibody class
      switching and antibody persistence).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Laboratory determination of presence of anti-SARS-COV2 antibodies (IgM, IgA, and IgG)</measure>
    <time_frame>testing will be performed within 2 days of collection</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Sample Collection Method</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects will provide samples via traditional phlebotomy, finger-stick, and saliva collection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>comparison of sample collection methods</intervention_name>
    <description>Samples will be collected via finger-stick, saliva collection, and traditional phlebotomy to determine effects on COVID-19 antibody test results.</description>
    <arm_group_label>Sample Collection Method</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed presence (N = 200) or absence (N = 100) of anti-SARS-COV2 antibodies

          -  &gt;17 years old

        Exclusion Criteria:

          -  Refusal or inability to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen A Varvel, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Salveo Diagnostics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen A Varvel, PhD</last_name>
    <phone>18048364439</phone>
    <email>svarvel@salveodiagnostics.com</email>
  </overall_contact>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2020</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

